Table 1 Table provides summary statistics for antibody study participants. Panel A. Full study period from May 2021-June 2022. For 117 people who received both Abbott and Roche spike protein tests in February-March 2022, 2 were positive for Roche but not Abbott; 0 were positive for Abbott but not Roche. For 112 vaccinated people who received both Abbott and Roche nucleocapsid tests in Feb-March 2022, 16 were positive for Roche but not Abbott; 0 were positive for Abbott but not Roche. The one unvaccinated but infected person (based on the survey) with a negative antibody test received the Abbott capsid test. Panel B. Period from April-June 2022. All participants received Roche tests. Both panels. Totals for male and female columns do not sum to total for all persons due to missing values.
All | % | Male | % | Female | ||
|---|---|---|---|---|---|---|
Panel A. Full Sample Period (May 2021-June 2022) | ||||||
Participants | 2,697 | 100% | 898 | 33.30% | 1,736 | 64.37% |
Race/ethnicity | ||||||
Black | 542 | 20.10% | 174 | 19.38% | 355 | 20.45% |
Hispanic (Non-Black) | 340 | 12.61% | 109 | 12.14% | 220 | 12.67% |
Non-Hispanic White | 1,619 | 60.03% | 553 | 61.58% | 1,032 | 59.45% |
Non-Hispanic Asian | 95 | 3.52% | 31 | 3.45% | 61 | 3.51% |
Other and missing | 101 | 3.75% | 31 | 3.45% | 68 | 3.92% |
Mean age (years, at date of survey) | 55.50 | - | 58.17 | - | 54.40 | - |
Vaccinated | 2,494 | 92.47% | 826 | 91.98% | 1,610 | 92.74% |
Infected based on survey | 421 | 16.88% | 132 | 15.98% | 278 | 17.27% |
Infected (nucleocapsid test) | 443 | 17.76% | 149 | 18.04% | 283 | 17.58% |
Mean age | 55.97 | 58.65 | 54.89 | |||
Unvaccinated | 203 | 7.53% | 72 | 8.02% | 126 | 7.26% |
Infected based on survey | 52 | 25.62% | 18 | 25.00% | 32 | 25.40% |
Infected (spike protein test) | 107 | 52.71% | 40 | 55.56% | 64 | 50.79% |
Mean age | 49.66 | 53.03 | 47.93 | |||
Unvaccinated and infected based on survey | ||||||
Infected (spike protein test) | 51 | 98.08% | 18 | 100.00% | 31 | 96.88% |
Unvaccinated with no knowledge of infection per survey | 151 | 54 | 94 | |||
Infected (based on spike test) | 56 | 37.58% | 22 | 40.74% | 33 | 35.87% |
Panel B. Last Three Sample Months, from April-June 2022 | ||||||
Participants | 527 | 100% | 176 | 33.40% | 336 | 63.76% |
Race/ethnicity | ||||||
Black | 89 | 16.89% | 33 | 18.75% | 53 | 15.77% |
Hispanic (Non-Black) | 101 | 19.17% | 40 | 22.73% | 57 | 16.96% |
Non-Hispanic White | 290 | 55.03% | 90 | 51.14% | 193 | 57.44% |
Non-Hispanic Asian | 23 | 4.36% | 8 | 4.55% | 15 | 4.46% |
Other and missing | 24 | 4.55% | 5 | 2.84% | 18 | 5.36% |
Mean age (years, at date of survey) | 53.42 | - | 56.10 | - | 52.44 | - |
Vaccinated | 497 | 94.31% | 167 | 94.89% | 316 | 94.05% |
Infected based on survey | 141 | 28.37% | 42 | 25.15% | 93 | 29.43% |
Infected (nucleocapsid test) | 205 | 41.25% | 72 | 43.13% | 125 | 39.56% |
Unvaccinated | 30 | 5.69% | 9 | 5.11% | 20 | 5.95% |
Infected based on survey | 8 | 26.67% | 0 | 0.00% | 7 | 35.00% |
Infected (spike protein test) | 26 | 86.67% | 8 | 88.89% | 17 | 85.00% |
Unvaccinated and infected based on survey | ||||||
Infected (spike protein test) | 8 | 100.00% | 0 | - | 7 | 100.00% |
Unvaccinated with no knowledge of infection per survey | 22 | 9 | 13 | |||
Infected (based on spike test) | 18 | 81.82% | 8 | 88.89% | 10 | 76.92% |
